Hydroxychloroquine doesn’t help COVID-19 patients

Researchers at the University of Oxford in the U.K. have concluded that hydroxychloroquine does nothing to prevent COVID-19-related deaths.

The research is a continuation of a major clinical trial that found that the drug — which has previously been touted by President Donald Trump and White House trade adviser Peter Navarro — had no clinical benefit.

The study, published in the New England Journal of Medicine, examined the outcomes of 1,561 patients hospitalized with COVID-19 who received hydroxychloroquine and compared them to 3,155 patients who served as a control group.

Within a month, about a quarter of the patients in each group had died.

There was also a slightly higher number of heart-related deaths in the hydroxychloroquine group; however, that finding was not robust enough to be statistically significant — meaning it could have been due to chance.

“The scientific evidence is clear,” said Dr. Caleb Alexander, a professor of

Read More

Rudy Giuliani taking hydroxychloroquine to fend off COVID-19 despite safety concerns

NEW YORK — Rudy Giuliani will apparently never get off the hydroxychloroquine train.

The ex-New York mayor told the New York Daily News on Wednesday that he’s taking the anti-malarial drug as a preventative measure against COVID-19 — even though U.S. regulators advise against it over concerns that the medication can cause serious side effects.

Giuliani, 76, stressed that he has tested negative for the virus several times in the past few days, but said his doctor recommended the hydroxychloroquine regimen since he spent considerable time last week with President Donald Trump and others who have since tested positive.

“All negative so far and no symptoms but I am taking hydroxychloroquine and zinc as a prophylactic,” said Giuliani, who’s these days best known as Trump’s combative personal lawyer. “A study in Italy showed exceptional results.”

Despite Giuliani’s claim that he’s not experiencing symptoms, a source familiar with the matter told

Read More

Study shows hydroxychloroquine did not prevent coronavirus in health care workers

A new study has found that hydroxychloroquine, the anti-malaria drug that President TrumpDonald John TrumpTrump signs bill averting shutdown after brief funding lapse Privacy, civil rights groups demand transparency from Amazon on election data breaches Facebook takes down Trump campaign ads tying refugees to coronavirus MORE said he took to ward off coronavirus, did not prevent COVID-19 among health care workers.

The study, published Wednesday in the journal JAMA Internal Medicine, was conducted at two urban hospitals between April 9-July 13 among 132 full-time health care workers exposed to the virus. However, the trial was ended early.

Some participants were given 600 mg daily doses of hydroxychloroquine while others were given a placebo for eight weeks.

“There was no significant difference in infection rates in participants randomized to receive hydroxychloroquine compared with placebo,” the researchers from the University of Pennsylvania wrote.

Four of the 64 healthcare workers who

Read More

Trump-touted hydroxychloroquine shows no benefit in COVID-19 prevention: study

(Reuters) – A malaria drug taken by U.S. President Donald Trump to prevent COVID-19 did not show any benefit versus placebo in reducing coronavirus infection among healthcare workers, according to clinical trial results published on Wednesday.

The study largely confirms results from a clinical trial in June that showed hydroxychloroquine was ineffective in preventing infection among people exposed to the new coronavirus.

Trump began backing hydroxychloroquine early in the pandemic and told reporters in May he started taking the drug after two White House staffers tested positive for COVID-19. Studies have found the drug to offer little benefit as a treatment.

In the study of 125 participants, four who had taken hydroxychloroquine as a preventative treatment for eight weeks contracted COVID-19, and four on placebo tested positive for the virus.

All eight were either asymptomatic or had mild symptoms that did not require hospitalization, according to the results published in

Read More

Hydroxychloroquine Market to Garner $4.6 Billion, Globally, By 2027 at 7.9 % CAGR, Says Allied Market Research

– Increase in demand for HCQ as a potential treatment option amidst the Covid-19 pandemic and surge in cases of malaria drive the growth of the global hydroxychloroquine market.

PORTLAND, Ore., Sept. 28, 2020 /PRNewswire/ — Allied Market Research published a report, titled, “Hydroxychloroquine Market by Product Type (Tablet and Active Pharmaceutical Ingredients), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Specialty Drug Store, and Retail Pharmacy), and Disease (Malaria, Rheumatoid Arthritis, Lupus Erythematosus, Coronavirus, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027.” According to the report, the global hydroxychloroquine industry generated $1.9 billion in 2019, and is expected to generate $4.6 billion by 2027, witnessing a CAGR of 7.9% from 2020 to 2027. 

Allied_Market_Research_Logo
Allied_Market_Research_Logo

Prime determinants of growth

Increase in demand for HCQ as a potential treatment option amidst the Covid-19 pandemic and surge in cases of malaria drive the growth of the global hydroxychloroquine market. However, ban in

Read More